Inogen (INGN) Net Income towards Common Stockholders (2013 - 2026)
Inogen (INGN) posted quarterly Net Income towards Common Stockholders of -$8.3 million for Q1 2026, down 31.39% year-over-year from -$12.1 million in Q1 2025, and down 199.44% quarter-over-quarter from $8.3 million in Q4 2025.
Inogen (INGN) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Inogen (INGN) has reported Net Income towards Common Stockholders for 14 consecutive years, with -$8.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 31.39% year-over-year to -$8.3 million; the TTM figure through Mar 2026 stood at -$10.7 million (up 49.95% YoY), while the FY2025 annual figure was -$8.7 million, up 70.33% from the prior year.
- Net Income towards Common Stockholders slipped to -$8.3 million in Q1 2026 per INGN's latest filing, from $8.3 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $72.5 million in Q4 2023 and bottomed at -$55.8 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$7.8 million across 5 years, with a median of -$6.3 million in 2025.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 1314.18% — and 2025, when it surged 342.69%.
- Inogen's Net Income towards Common Stockholders stood at -$55.8 million in 2022, then jumped by 229.8% to $72.5 million in 2023, then tumbled by 104.74% to -$3.4 million in 2024, then soared by 342.69% to $8.3 million in 2025, then slumped by 199.44% to -$8.3 million in 2026.
- Business Quant data shows INGN's Net Income towards Common Stockholders at -$8.3 million in Q1 2026, $8.3 million in Q4 2025, and -$5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Inogen | 151.72 Mn | 46.18 Mn | 43.27 Mn | -3.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.69 Mn |
| Mar 31, 2026 | -8.29 Mn |
| Dec 31, 2025 | 8.33 Mn |
| Sep 30, 2025 | -5.95 Mn |
| Jun 30, 2025 | -4.76 Mn |
| Mar 31, 2025 | -6.31 Mn |
| Dec 31, 2024 | -3.43 Mn |
| Sep 30, 2024 | -5.96 Mn |
| Jun 30, 2024 | -5.59 Mn |
| Mar 31, 2024 | -14.58 Mn |
| Dec 31, 2023 | 72.46 Mn |
| Sep 30, 2023 | -45.71 Mn |
| Jun 30, 2023 | -9.83 Mn |
| Mar 31, 2023 | -20.35 Mn |
| Dec 31, 2022 | -55.83 Mn |
| Sep 30, 2022 | -9.51 Mn |
| Jun 30, 2022 | -2.84 Mn |
| Mar 31, 2022 | -13.76 Mn |
| Dec 31, 2021 | -22.56 Mn |
| Sep 30, 2021 | 12.28 Mn |